




CAPSERO

INVESTMENT DECK 2025

Regulatory precision, revolutionary
phytointelligence - CAPSERO as your
partner in the regulated industry

DISCLAIMER



Head office: CAPSERO AG, Dammstrasse 36, 4142 Münchenstein, Switzerland | **Operations:** CAPSERO AG, Schaffhauserstrasse 101, 4332 Stein, Switzerland

The information contained in this presentation is confidential and for your personal reference only. This information is subject to change without notice, its accuracy is not guaranteed and it may not contain all material information about CAPSERO AG (the "Company"). The Company assumes no responsibility or liability for the accuracy or completeness of the information contained herein or for any errors or omissions in such information. In addition, the information contains projections and forward-looking statements that may reflect the Company's current views with respect to future events and financial performance. These views are based on current assumptions that are subject to various risks and may change over time. There can be no assurance that future events will occur, that the forecasts will be achieved or that the company's assumptions will prove correct. It is not intended to provide a complete or comprehensive analysis of the Company's financial or trading position or prospects and you should not rely on this presentation. This presentation does not constitute an offer or invitation to purchase or subscribe for any securities or financial instruments or to provide any investment services or advice and no part of this presentation shall form the basis of, or be relied upon in connection with, any contract, commitment or investment decision whatsoever in relation thereto. .

WHY NOW?

FIRST THINGS FIRST



⊗ We do not grow plants and do not operate vertical farms!

- ✓ CAPSERO is the first company in the world to offer a modular, fully automated, sterile and legally compliant technology platform for the production of raw materials for phytopharmaceuticals, cosmetics and plant-based foods.
- ✓ Consistent quality and quantity, with full traceability and compliance with GMP/GACP/GAMP5
- ✓ Scalable, patented technology enables market penetration

Regulatory upheaval requires safe production methods.

LEGAL CHANGES & MARKET UPHEAVAL



The EU, Switzerland and the USA tightened the regulations for plant-based medicine, cosmetics and food in 2023 and 2024.

Historically, regulatory changes have regularly consolidated markets and created new market leaders. The market upheaval is imminent.

- ✓ Thalidomide scandal (1960s): Stricter approval controls created a new regulatory environment for pharmaceutical companies.
- ✓ PIP scandal (2010): Following the discovery of industrial silicone in breast implants, the EU introduced strict material controls - only companies with complete traceability benefited.
- ✓ Sterility incidents in drug production: Tightening of FDA and EMA regulations made strictly regulated production mandatory.
- ✓ EFSA screening (food safety): New regulations for contaminants and heavy metals forced producers to make changes.

CAPSERO offers the first fully compliant, scalable and automated solution and is therefore the answer to the current regulatory challenges

LEGAL CHANGES & MARKET UPHEAVAL



Incident	Problem	Regulation	Duration until settlement
Thalidomide scandal	Mutagen for unborn children, October 1957	01.08.1961	4 years
Chernobyl	Explosion at the nuclear power plant in April 1986 with radioactive contamination of salads	Ban on the provision of salads from May 1986 - July 1988	Immediately
PIP scandal	Renewal of the Medical Device Directive (MDD) due to the breast implant scandal in April 2010	25.05.2017	7 years
AI development	AI Act to protect the population from strong AI and data protection issues following incidents in 2019	21.05.2024	5 years
Sterility incidents with sterile medicinal products	Advances in the manufacture of sterile medicinal products and implementation of ICH Q9 and Q10 in EU GMP in 2017 led to the update of GMP Annex I	25.08.2023	5 years
EFSA screening	Elevated levels of pyrrolizidine alkaloids found in tea and herbs in 2011	Setting lower limits for pyrrolizidine alkaloids in tea and herbs as of 2016	5 years
EFSA screening	Evaluation of toxicity information on fluroxypyr in chives, celery leaves, parsley, thyme, basil and edible flowers in 2017	Setting lower limits for fluroxypyr by 2020	3 years

LEGAL CHANGES & MARKET UPHEAVAL



ADAPTED LEGAL SITUATION

In 2020, the EFSA (European Food Safety Authority) defined or lowered the maximum levels of various substances in plant raw materials. These substances mostly occur due to contamination in outdoor cultivation.


Find out more at: <https://www.efsa.europa.eu/de/efsajournal/pub/6273>

The European Union has implemented a harmonization of medicinal plants at EU level by updating the law. This has massively tightened the quality requirements and now requires GACP/GMP.

Read more: <https://eurlex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2004:136:0085:0090:en:PDF>

The lists of plants to which the directives apply can be found in the annexes to the EU law below:

<https://eur-lex.europa.eu/legal-content/DE/ALL/?uri=celex%3A32005R0396>

 In outdoor cultivation, for example, aloe vera absorbs nutrients via its roots and thyme via its roots. The leaves contain harmful substances, which means that further processing of the plants is prohibited.

AFFECTED REGIONS / AUTHORITIES



EFSA

European food safety

**2001/83/EC
(EU GMP)**

European regulation for
pharmaceuticals

**1223/2009/EC
(ISO 22716, GMP)**

European regulation for
cosmetics

**FDA
(FSMA)**

USA Food safety

**FDA 21 CFR 210/211
(US GMP)**

USA regulation for
pharma

**FD&C Act (MoCRA)
(ISO 22716, GMP)**

US regulation for
cosmetics

THE PRESSURE ON PRODUCERS IS INCREASING

Current production methods are unreliable, inefficient and no longer future-proof.

Strict regulations:

- New EU regulations on limiting pesticides and heavy metals.
- FDA/EMA requirements for sterility and traceability.
- GMP/GACP conformity becomes mandatory for market access.

Contamination problems:

- 25% of the world's arable land is unusable due to heavy metals, pesticides and environmental toxins.
- 14% of the harvested raw materials are lost during transportation.

Cost explosion for quality assurance:

- Cleaning, testing and traceability account for up to 30 % of production costs.

Conclusion: Producers urgently need to switch to standardized, clean, traceable production methods - otherwise they will lose market share or approvals.

We provide a safe haven for customers, manufacturers and distributors of plant raw materials in the highly regulated industry following the recent legislative changes.

Welcome to CAPSERO!

OVERVIEW



Task	Company
Series A	CAPSERO AG, Switzerland
CEO	Fabio Cirillo
Rating	PWC, Switzerland
Market data	Statista, Germany
Feasibility study	Innosuisse - Swiss Agency for Innovation Promotion
University partner	Zurich University of Applied Sciences, University of Basel, University of Montpellier
Legal advice	BBP, Switzerland; CMS, Switzerland
Corporate business	Valiant Bank, Switzerland

MANAGEMENT SUMMARY



1

CAPSERO is the only company in the world that **guarantees** technology and service for sterile, **contamination-free, certifiable and traceable cultivation of plant material right through to the end product.**

2

Starting with controlled plants, CAPSERO offers industrial quantities of identical, sterile seedlings for fully automated cultivation and harvesting using patented processes and technologies.

3

Using big data, machine learning and AI, CAPSERO can **optimize plant growth live according to desired criteria** and even predict results.

VISION

Our goal is to provide humanity with clean, safe and optimized plant-based solutions that improve health, sustainability and the future of regulated industries



FOUNDER STORY



FABIO CIRILLO
CEO AND CTO
CO-FOUNDER

"I worked with green tea, star anise and dyer's weed for a long time, and since the environmental influences during cultivation cannot be 100% controlled, a plant always develops slightly differently."

I am Fabio Cirillo, founder and CEO of CAPSERO. I am a chemist and process engineer by training, an amateur astronomer and always enthusiastic about technology, curious and willing to explore new ways to solve old problems. I grew up in the various Big Pharmas of the world and worked in international project management in Europe, the USA and Asia, particularly in the construction of large-volume pharmaceutical and natural product production plants. With blood, sweat and tears, we literally built huge production facilities for several hundred thousand tons of product per year. In this context, I have of course also been intensively involved in natural product chemistry and am the inventor of many patents and have played a key role in drug approval.

"The recurring problem with natural product extraction was the procurement and quality control of plant source material. In my case, this meant that production facilities had to be stopped, the plant material analyzed and the process readjusted. You can imagine the costs associated with such an interruption in production."

FABIO CIRILLO, CEO



FABIO CIRILLO
CEO AND CTO
CO-FOUNDER

- ✓ Chemist, Chemical Process Engineering (ZHAW)
- ✓ Certificate in User-Centered Product and Service Design (Cornell University)
- ✓ Certificate in Business Strategy (Cornell University)

Leading positions in large pharma and medtech companies in research and development with a focus on global product development and technical engineering. Founder of a renowned, award-winning consulting company in Europe. Chairman and guest speaker at various congresses and training providers.

Over 30 products
launched on the global
market

Over 10 patents for
large-scale industry and
pharmaceuticals

pharmaceutical and
industrial process plants
and managed the
construction

Keynote speaker and
chairman at
international life science
congresses


OUR TEAM



BENJAMIN
RUTZ
CMO AND
CO-FOUNDER

With a background in international Management (FHNW), extensive experience in the start-up industry and has been involved in marketing and growth strategies for both own projects and small companies, focusing on the automation of marketing, sales and customer retention processes. Involved in marketing projects in the medicinal plant, active ingredient and chemical industries.

PART 3: TEAM



TEAM AND PARTNERS



CAPSERO manages and coordinates > 50 engineers, technicians, researchers, agronomists, data and AI specialists who all contribute to the success of the technology.

Our corporate team consists of experts and consultants who are highly experienced, educated and extensively trained in their respective fields. These areas are critical to the value and growth of CAPSERO and its proprietary methodologies and are as follows:

Engineering sciences



ICT



Research



Biology/biotechnology



THE PROBLEMS IN NUMBERS



1

Contamination

25% of the world's farmland is contaminated

2

Purification

Purification accounts for 20%-30% of production costs

3

Transportation

Loss of 14% caused by transportation worldwide

4

Diseases

Worldwide 20%-40% loss due to disease

5

Quality system

Insufficient standardization and traceability

6

Inconsistency

Differences in quality and quantity slow down processing

7

Plannability

Dependence on environmental influences reduces planning reliability

8

Optimization

Plant protocols are not optimized using modern methods

THE PROBLEMS

What has been recognized so far:

- Food shortage
- Population growth
- Crop failures
- Environmental influences

Quality and traceability

Quality checks only show pests and contamination at random, without tracing the production chain

Efficiency and optimization

Manual interventions on a system that has been created once without the possibility of simply introducing optimizations.

Decentralized and local producers

Produced locally on large farms and distributed by truck over a large catchment area.

Consistency and planning security

Planning reliability and consistency of quality, quantity of ingredients or quantity make planning reliability in the value chain more difficult

But we go one step further!

THE SOLUTION



We strive to build a sustainable, fail-safe, efficient and decentralized network of automated, locally installed cultivation facilities to ensure a 100% supply of humanity with all the plant raw materials it needs.

- ✓ Fully automated cultivation technology in containers
- ✓ Re-supply with DNA-pure plant capsules
- ✓ Ideal breeding programs, tailored to the plant genome
- ✓ 100% contamination-free, aseptic production
- ✓ Stackable, modular and scalable container farms



THE SOLUTION VISUALIZED




TECHNOLOGY



Watch the video

OPTIMIZATION



Watch the video

INDUSTRIAL DAYS (HANDHELD VIDEO)



Watch the video

<https://youtu.be/fUOWXmm2DaA>

BUSINESS MODEL & MONETIZATION

OUR BUSINESS MODEL



CAPSERO range

Customers can currently choose from over 80 plants from our plant vault.



Proprietary plant

We can clone customer-specific plants in vitro and propagate and maintain them proprietarily for the customer.

Additional services

- ✓ Plant optimization
- ✓ Digital Twin Simulations
- ✓ CAPSERO DNS Vault
- ✓ Quality system
- ✓ Service Level Agreement
- ✓ Consumables



Propagation

In our laboratories, we propagate plants from our range in large numbers under sterile conditions and fully documented.



Cultivation protocol

Using state-of-the-art technologies, we can not only create fast, but also optimized cultivation protocols.



GROW Container

The GROW Container is the heart of every farm and is supplied as a plug-n-play, modular system that can be expanded at any time.



HARVEST Container

The HARVEST container serves up to 10 GROW containers, works completely automatically and takes on both cleaning and planting tasks.



PROCESSING Container

The PROCESSING container is individually tailored to the process, equipped and, if required, fully qualified on site.



Marketplace

A virtual place to organize the global demand for plants and raw materials. If desired, the marketplace communicates with the farm and/or external laboratories.

REVENUE SOURCES



Revenue Stream	Kind	Explanation	Margin	Share of sales (2029)
Sale of grow containers	One-off Revenue	Sale of modular, patented production containers to customers	100%	38%
Sale of plant capsules	Recurring	Regular supply of sterile plant capsules for cultivation in the CAPSERO system	500%	38%
Software and quality system licenses	Recurring	SaaS model for AI-supported growth protocols and regulatory compliance documentation	100%	9%
Marketplace fees	Recurring	Commission on the trading of regulated plant commodities via the CAPSERO marketplace	5-10 %	10%
SLA service contracts	Recurring	Premium support for customers with guaranteed availability & regulatory compliance	70-90 %	5%

CUSTOMER EXAMPLE | LIFE CYCLE



Product	Quantity	Price	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	Total	Share
GROW module	6	250'000	1'500'000										1'500'000	30.1%
HARVEST module	1	500'000	500'000										500'000	10.0%
Non-recurring revenue													2'000'000	40.1%
Capsules	23'328	8.50	198'288	198'288	198'288	198'288	198'288	198'288	198'288	198'288	198'288	198'288	1'982'880	39.8%
Consumables	6	1'200	7'200	7'200	7'200	7'200	7'200	7'200	7'200	7'200	7'200	7'200	72'000	1.4%
Software	6	7'500	45'000	45'000	45'000	45'000	45'000	45'000	45'000	45'000	45'000	45'000	450'000	9.0%
GMP/GACP	1	12'000	12'000	12'000	12'000	12'000	12'000	12'000	12'000	12'000	12'000	12'000	120'000	2.4%
Service and SLA	6	6'000	36'000	36'000	36'000	36'000	36'000	36'000	36'000	36'000	36'000	36'000	360'000	7.2%
Recurring revenue													2'984'880	59.9%
Total sales			2'298'488	298'488	298'488	298'488	298'488	298'488	298'488	298'488	298'488	298'488	4'984'880	100%

40%

One-time turnover:
CHF 2'000'000

60%

Recurring revenue:
CHF 2'984'880

TECHNOLOGY

OUR TECHNOLOGY



A

PLANT

> **100** protocols
from catalog
available

B

CONTAINER

Production capacity of
52 containers per
year, rising

C

CAPSULE

Ready for
industrial
Manufacturing

D

MARKETPLACE

First contracts under
negotiation;
Marketplace ready
for roll-out

E

CLOUD

CLOUD is ready for
data acquisition and
data analysis

F

DIGITAL TWIN

Hardware under
construction;
algorithms verified in
silico

A) PLANT

- Technology Readiness Level (TRL) 8
- Over 100 plant protocols and associated storage culture
- Automation of cloning
- AI solution for the rapid creation of plant protocols




B) CONTAINER

- Technology Readiness Level (TRL) 7
- Production capacity of 50 containers per year, expansion to 50 containers per month
- 1 manufacturer qualified in Europe, 4 more in qualification
- Production time per container 3 months, reduction to 1 month



C) CAPSULE

- Technology Readiness Level (TRL) 7
- Safe to transport, even in an airplane
- Plant shelf life > 14 days
- Sterilizable
- Automatically openable
- For all plants




D) MARKETPLACE


- Technology Readiness Level (TRL) 5
- eShop for all products and services
- Connects buyers with sellers
- Ensures certification and quality

 Search plant materials

Buy




E) CLOUD



F) DIGITAL TWIN


- Technology Readiness Level (TRL) 5
- CAPSERO-GPT for fast protocol generation
- R&D equipment for measuring the plants and validating the parameters
- Statistical model for optimization and validation



OUR PROMISE



CAPSERO COMPARED TO CONVENTIONAL INDOOR FARMS

A photograph of a small green seedling with two leaves growing out of a white ceramic pot, which sits on a grey surface. The background is a soft-focus grey.

REGULATORY	ECOLOGICAL	FINANCIAL	ECONOMIC
complete GMP compliant	30% Less water	60% less operating costs/m ²	50% Time saving until the harvest
100% free from pesticides	50% Less energy	9 months until amortization of the investment	80% more yield per m ²
100% Traceable	25% less CO ₂	50% less investment costs/m ²	90% less Personnel costs
compliant on the QbD approach (Quality by Design)	100% contamination free	100% Covering the Earnings risk (insurance)	>25% more harvests per year
100% Automated and AI-controlled	100% modular, scalable and flexible		

MILESTONES

MILESTONES

2018	2019	2020	2021	2022
<ul style="list-style-type: none">✓ Origin of the idea✓ First solution approaches	<ul style="list-style-type: none">✓ Development of the technical solution to the problem✓ Market analysis✓ Concepts for monetization✓ Evaluation of the core team	<ul style="list-style-type: none">✓ Company foundation✓ Organization of the company structure✓ Development of the partner network and advisory✓ Development and implementation of the QMS✓ Development and POC construction✓ Filing the patent	<p><i>Corona crisis</i></p> <ul style="list-style-type: none">✓ Conclusion POC✓ Conclusion Development of the technology✓ Tender manufacturer✓ Software and AI algorithms	<ul style="list-style-type: none">✓ Scaling of production✓ Industrialization✓ Automation solutions✓ Innosuisse

MILESTONES


Q1 2024		Q2 2024	Q3 2024	Q4 2024	FUTURE
	<ul style="list-style-type: none">✓ Conclusion of contracts with distribution and production partners✓ Staffing✓ Nationalization of patents	<ul style="list-style-type: none">✓ Product launch✓ Implementation of the LOIs✓ Nationalization of patents	<ul style="list-style-type: none">✓ Market entry in the DACH region✓ Automation concept✓ Concept of protocol generation	<ul style="list-style-type: none">✓ CAPSERO-GPT✓ Manufacturer qualification✓ Move into production areas✓ Staffing	<ul style="list-style-type: none">✓ Vertical integration of the core businesses✓ Market expansion EU✓ Further market entries✓ EXIT strategy

HIGHLIGHTS

Startup coaching
Business Check
INNOSUISSE



INNOSUISSE
Subsidies
receive



Patent on
World Patent Office
published



Google Startup Award
EURO 100'000.-

AVEVA Lighthouse
Project

First sales:
Sales target 2023/24 by
60% exceeded

Letters of intent for more
than 1300 containers

Positive discussions with
more than 80 customers
from the pharmaceutical
and cosmetics industries

Rollout of the 0 series
in 2023
Onboarding of large-scale
producers completed

TRACTION

Course of business

- Product development under GMP completed
- CMO for production
- Over 80 in-vitro protocols developed
- Patent published at WIPO, Nationalization
- Key positions covered and candidates identified for other positions

Awards

- INNOSUISSE Business Check successfully completed
- INNOSUISSE receives funding
- Google Startup Award received
- Member of Piccard's Solar Impulse Foundation
- Selected by Startus Insights as top 10 companies in the AgTech sector

Known from



Zefyron

StartUs
insights

Google for Startups

AVEVA



urban | vine

SUSTAINABILITY

SUSTAINABLE | SOLAR IMPULSE




Betrand Piccard's Solar Impulse Foundation has invited us as CAPSERO to have our solution for the sustainable and controlled cultivation of active ingredient plants evaluated under the "efficient solution" label. The rigorous assessment covers various aspects such as resource consumption, the impact on education and employment conditions and the ecosystem.

Sustainability study by Solar Impulse

This study shows that the ecological footprint of basil is reduced by 67% through the use of the CAPSERO solution. This is mainly due to the fact that less water and electricity are required during the use phase.



SOLAR IMPULSE STUDY



SOLARIMPULSE
FOUNDATION

<https://solarimpulse.com/companies/capsero>

WHAT THE FUTURE HOLDS

Sustainability is not just a word for us.

We are already planning ahead for the new present of sustainable agriculture!

- ✓ Waste biomass is used to produce biogas
- ✓ Biogas is used to supply the company with energy
- ✓ Waste from biogas is CO₂ and fertilizer
- ✓ Fertilizer is used to prepare the seedlings
- ✓ CO₂ is used to grow the seedlings on the farm
- ✓ Decentralized food production with physical blockchain
- ✓ Use of solar and water energy
- ✓ Using direct seawater replenishment for the cultivation of crops
- ✓ Rapid reforestation with healthy trees that are resistant to pests

OUR CUSTOMERS

CASE STUDY



ARGENT. HARDWARE

Verbena bonariensis

Number of plants: 3'150
Yield/harvest: 630 kg
Turnover/harvest: CHF 693,000

**At least 4 harvests
per year possible**

*Imputed sales prices



BAIKAL FEVERFEW

Scutellaria baicalensis

Number of plants: 3'150
Yield/harvest: 315 kg
Turnover/harvest: CHF 78'750

**At least 4 harvests
per year possible**

*Imputed sales prices



MED. CANNABIS

Cannabis sativa

Number of plants: 1'052
Yield/harvest: 63 kg
Turnover/harvest: CHF 283,500

**At least 4 harvests
per year possible**

*Imputed sales prices

By the way:

- ✓ 1680 containers fit on a football pitch.
- ✓ This corresponds to 1.76 - 5.29 million plants.



COSMECEUTICAL MARKET


Cosmeceuticals are cosmetic products with bioactive ingredients that are said to have a medicinal effect. Extracts and substances that are identical to the skin, ideally matched to each other and can be optimally absorbed by the skin are the secret of the cosmeceutical effect.



The global market for cosmeceuticals


is expected to grow from USD 54.57 billion in 2022 to USD 96.23 billion in 2029, at a CAGR of 8.4% during the forecast period 2022-2029.

Market size in USD billion



<https://www.fortunebusinessinsights.com/cosmeceuticals-market-102521>

Global Cosmeceuticals Market Share, By Product Type, 2021



WELL-KNOWN COMPANIES



L'Oréal
Annual sales: 32.28 billion USD
Number of employees: 85,400



Estée Lauder
Annual sales: 14.29 billion USD
Number of employees: 22,000



Kao Corporation
Annual sales: 11.12 billion USD
Number of employees: 33,500



Unilever
Annual turnover: 52.44 billion USD
Number of employees: 149,000



Coty
Annual sales: 9.4 billion USD
Number of employees: 10,600



Beiersdorf
Annual sales: 7.65 billion USD
Number of employees: 20,000



Procter and Gamble
Annual turnover: 67.7 billion USD
Number of employees: 97,000



Shiseido
Annual sales: 6.47 billion USD
Number of employees: 33,000



Johnson & Johnson
Annual sales: 71.9 billion USD
Number of employees: 127,000

WELL-KNOWN PLANTS



Aloe vera extract
Annual sales: 2.3 billion USD

<https://www.statista.com/statistics/688799/global-sales-of-aloe-vera-extract/>



Lavender extract
Annual sales: 3.53 billion USD

<https://www.tridge.com/intelligences/lavender-oil>



Rosemary extract
Annual sales: 3.3 billion USD

<https://www.tridge.com/intelligences/rosemary1/production>



Safflower extract
Annual sales: 9.14 billion USD

<https://www.tridge.com/intelligences/safflower-oil>



Hibiscus extract
Annual sales: 3.3 billion USD

<https://www.tridge.com/intelligences/hibiscus>



Sea buckthorn extract
Annual sales: 3.55 billion USD

<https://www.tridge.com/intelligences/sea-buckthron>

 **TRIDGE**




<https://www.tridge.com>
Global Sourcing Hub of
Food & Agriculture

PHYTOPHARMA MARKET



The global **herbal medicines** market is expected to grow from USD 230.03 billion in 2021 to USD 430.05 billion by 2028, at a CAGR of 11.32%.

Europe Herbal Medicine Market Size, 2017-2028 (USD Billion)



A full 40 percent of the drugs that cross pharmacists' counters in the Western world are derived from plants that people have used for centuries, including the top 20 best-selling prescription drugs in the United States.

<https://www.fs.fed.us/wildflowers/ethnobotany/medicinal/index.shtml>

<https://www.fortunebusinessinsights.com/herbal-medicine-market-106320>

WELL-KNOWN PLANTS



Echinacea (Echinacea)

annual turnover:
2.88 billion USD in 2028

<https://www.verifiedmarketresearch.com/product/echinacea-extract-market/>



Elderberry

annual turnover:
6.87 billion USD in 2027

<https://www.maximizemarketresearch.com/market-report/global-elderflower-market/94093/>



Camomile

annual turnover:
412 billion USD in 2025

<https://www.globenewswire.com/news-release/2020/06/15/2047865/0/en/Chamomile-Market-to-hit-US-412-billion-by-2025-Global-Insights-on-Key-Trends-Size-Value-Chain-Analysis-Leading-Players-Growth-Drivers-Recent-Initiatives-and-Business-Opportunities.html>



Ginseng

annual turnover:
11.7 billion USD in 2026

<https://www.researchandmarkets.com/reports/5029877/ginseng-global-market-trajectory-and-analytics>



Turmeric

annual turnover:
4.3 billion USD in 2020

<https://www.industryarc.com/Report/19635/turmeric-market.html>



Ginkgo

annual turnover:
2.38 billion USD in 2028

https://www.einnews.com/pr_news/575015047/ginkgo-biloba-extract-market-size-worth-usd-2-379-2-million-by-2028-stellar-cagr-of-4-1



Ginger

annual turnover:
4.3 billion USD in 2027

<https://www.imarcgroup.com/ginger-market>



According to CITES, around 60,000 MAP (Medicinal and Aromatic Plants) are harvested worldwide.

OUR MARKET

THE RELEVANT MARKETS

Market	Size in CHF	CAGR	Market research institutes
Cosmetics with active plant ingredients	78 bn.	7.20%	Cognitive Market Research Mordor Intelligence, Fortune Business Insights, Globe News Wire
Plant-based medicine	21 bn.	14.70%	Cognitive Market Research, Business Research Insights, Grand View Research, Technavio
Natural cosmetics	37 bn.	5.70%	Grand View Research, The Business Research Company
Plant-based food supplement	4.5 bn.	7.32%	Grand View Research, Fortune Business Insights
Indoor farming	43 bn.	10.00%	Statista
Vertical Farming	6.8 bn.	10.00%	Statista
AgTech / AgriTech	24 bn.	16.50%	Zion Market Research
CEA (Controlled Environment Agriculture)	32 bn.	19.20%	Dimension Market Research
Agriculture	13'100 bn.	6.55%	Research and Markets

WEIGHTING OF MARKETS BY RELEVANCE

Market	Weighting
Phytopharmaceutical	16%
CEA	16%
Natural Cosmetics	14%
Cosmeceutical Market	14%
Plant-Based Supplements	12%
AgTech	12%
Vertical Farming	9%
Indoor farming	7%

2025

CHF 31.3 billion



**CAPSERO MARKET
IN THE YEAR 2032**

CHF 53.4 billion

TAM, SAM, SOM: INDOOR FARMING MARKET

YEAR 2025

TAM: 31.3 bn. USD

Sum of all relevant markets with weighting.

SAM: 16.5 bn. USD

Only phytopharmacy and cosmetics

SOM: USD 5.9 million

1) Pessimistic: 0.01% of the SAM
2) Realistic: 0.02% of the SAM
3) Optimistic: 0.05% of the SAM

YEAR 2032

TAM: 53.4 bn. USD

Only 74.5% of the TAM work with suitable breeding systems. Global market entry in relevant regions has been successful at this time.

SAM: 20.13 bn. USD

All relevant markets

SOM: 5.2 bn. USD

1) Pessimistic: 0.50% SAM
2) Realistic: 5.0% SAM
3) Optimistic: 9.7% of the SAM

TAM | Total available market

Global indoor farming market

SAM | Servable Available Market

Successful market entry, consideration of the comparable indoor breeding systems

SOM | Serviceable accessible market

CALCULATION OF THE SOM	2025	2026	2027	2028	2029	2030	2031	2032
PESSIMISTIC: Share of SAM	0.01%	0.02%	0.04%	0.08%	0.16%	0.24%	0.36%	0.42%
REALISTIC: Share of SAM	0.02%	0.15%	0.35%	0.40%	0.65%	1.00%	1.50%	3.00%
OPTIMISTIC: Share of SAM	0.07%	0.35%	0.68%	1.28%	2.13%	2.92%	5.29%	9.65%

MARKET LEADER VERTICAL FARMING



Competitors in vertical farming/smart farming stand out due to the following features:

- ✓ High deployment of people required
- ✓ No complete traceability
- ✓ Operated as an "indoor" solution
- ✓ Focused on food only
- ✓ Cross-contamination cannot be ruled out



	PlantLab	Plenty	BOWERY
Seat	Amsterdam, NL	California, USA	New York, USA
Industry	Food	Food	Food
Financing status/capital raised	Pre-IPO/57 million USD	Pre-IPO/941 million USD	Pre-IPO/750 million USD
Automation ¹	Deep	Medium	Medium
Sterile conditions	No	No	No
Complete traceability	No	No	No
Energy-efficient ²	Medium	High	Medium
Mutation monitoring	No	No	No
Irrigation technology	Aeroponics	Aeroponics	Hydroponics
Modular and decentralized use	No	No	No

1: Automation high = no people; medium = people and robots, low = only people | 2: Energy consumption high = hall with sufficient open spaces medium = deep rooms; low = minimum space requirement

DIRECT COMPETITORS



Property / Company	CAPSERO	MABEWO	CULTIVATD	FREIGHT FARMS
Individual industry Independent	✓	---	---	---
Mutation-free in-vitro plant	✓	---	---	---
Automated optimization	✓	---	---	---
Digital Twin Simulation	✓	---	---	---
GACP/GMP Compliant	✓	✓	---	---
Sterile production	✓	---	---	---
Fully automated	✓	✓	✓	✓
AI integration	✓	---	---	✓
Marketplace	✓	---	---	---
Scalable	✓	✓	✓	✓

1: Automation high = no people; medium = people and robots, low = only people | 2: Energy consumption high = hall with sufficient open spaces medium = deep rooms; low = minimum space requirement

SCALING & EXPANSION


SCALING THROUGH AUTOMATION



Automation of in-vitro cultivation and plant propagation

Part 1: In vitro cultivation

Part 2: Propagation



Challenge:

Customer requests for proprietary in-vitro protocols and varieties, production and filling of plant capsules and production of container modules to scale

Solution:


Automate in-vitro protocols and plant capsule production and scale container module production through contract manufacturers.

R&D Cultivation and Digital Twin

Automatic development of **cultivation protocols and optimization according to customer requirements** with high-throughput screening and design of experiment

Automatic creation of digital twins for **forecasting plant behavior** and feeding the data into our **database and artificial intelligence**

EXPANSION STRATEGY



FINANCES & KEY FIGURES

CAPACITY DECLARATIONS OF INTENT



	Year 1	Year 2	Year 3	Year 4	Year 5	Year 6
Container demand	50 (n=7)	135 (n=6)	181 (n=3)	128 (n=1)	250 (n=1)	312 (n=1)
Capacity	50 ¹	150 ³	200 ⁵	250	300 ⁷	400
Utilization	100%	90%	90.5%	51.2%	83.3%	78%
	Year 1	Year 2	Year 3	Year 4	Year 5	Year 6
Capsule demand	129'024	513'024	1'035'264	1'403'904	2'141'184	3'062'784
Capacity	144'000 ²	1'152'000 ⁴	1'152'000	2'304'000 ⁶	2'304'000	3'456'000 ⁸
Utilization	89.6%	44.5%	89.9%	60.9%	92.9%	88.6%

1: manual assembly, two-layer
2: Rapid Tool, single cavity

3: Semi-automatic assembly, single-shift operation
4: Industrial mold, 8 cavities

5: Semi-automatic assembly, single-shift operation
6: 2nd industrial mold, 8 cavities

7: Semi-automatic assembly, 2 locations
8: 2 industrial molds, 16 cavities

PART 13: FINANCES

FINANCIAL STATEMENTS



	2021	2022	2023
Turnover	CHF 0	CHF 185'701	CHF 564'299.00
Gross result	CHF -300'862	CHF 97'543	CHF 75'335.00
EBITDA	CHF -341'046	CHF 61'637	CHF 44'030.00
Profit/loss for the year	CHF -321'167	CHF 59'141	CHF 43'891.00

CAPSERO is ideally positioned to close the gap between increasing regulatory requirements and the limited availability of legally compliant production methods.

ASSUMPTIONS & EXPLANATIONS



CAPSERO's sales figures are based on a comprehensive market analysis and reflect the dynamic development of demand and scalable production capacities. The forecasts are not purely theoretical, but are based on specific market indicators:

- Securitized demand
- Regulation-driven market dynamics
- Production expansion & scaling
- Sustainable sources of revenue

Unit	Revenue per unit (CHF)	FY1 (2024)	FY2 (2025)	FY3 (2026)	FY4 (2027)	FY5 (2028)	FY6 (2029)	FY7 (2030)
R&D Container	500000	0	0	1	2	5	10	15
Grow Container	250000	2	20	42	96	192	420	720
Harvest Container	500000	0	1	2	5	10	21	36
Processing Container	500000	0	0	0	0	10	21	36
Capsules	5	0	81'920	174'080	397'312	796'672	1'740'800	2'979'840
Capsules recurring	5	0	8'192	81'920	174'080	397'312	796'672	1'740'800
GACP Workbench (40%)	15000	0	1	16.8	38.4	76.8	168	288
Protocols	2500	0	8	88	256	640	1408	3088
Marketplace	10000	0	8	88	256	640	1408	3088
Audit, QP, Annual Reporting	7250	0	1	16.8	38.4	76.8	168	288

FINANCIAL FIGURES OPTIMISTIC



Optimistic scenario in CHF							
Key figures	2024	2025	2026	2027	2028	2029	2030
Grow containers sold (indication)	2	20	60	125	300	650	1300
Total sales	500'000	5'822'810	19'183'840	40'235'620	104'054'080	228'213'800	457'502'800
EBITDA	-617'200	-629'573	3'169'544	13'027'568	54'640'358	138'078'669	306'726'573
EBITDA margin	0%	0%	17%	34%	55%	64%	71%
PAT margin	0%	0%	40%	48%	61%	66%	72%
Sales growth (YoY)	0%	0%	229%	110%	159%	119%	100%

FINANCIAL FIGURES REALISTIC



Realistic scenario in CHF							
Key figures	2024	2025	2026	2027	2028	2029	2030
Grow containers sold (indication)	2	20	42	96	192	420	720
Total sales	500'000	6'112'810	15'193'800	35'691'360	79'378'720	172'065'360	307'551'200
EBITDA	-394'379	1'007'794	2'370'486	10'824'405	39'484'624	104'481'094	208'130'612
EBITDA margin	0%	0%	0%	16%	46%	59%	68%
PAT margin	0%	0%	40%	47%	60%	65%	72%
Sales growth (YoY)	0%	0%	214%	151%	129%	115%	71%

FINANCIAL FIGURES PESSIMISTIC



Pessimistic scenario in CHF							
Key figures	2024	2025	2026	2027	2028	2029	2030
Grow containers sold (indication)	2	10	30	60	120	240	480
Total sales	500'000	3'408'010	11'436'440	23'847'920	49'466'080	100'202'400	199'113'600
EBITDA	394'379	38'696	604'529	4'667'914	21'215'980	57'358'645	131'357'930
EBITDA margin	0%	0%	0%	24%	53%	72%	83%
PAT margin	0%	0%	49%	61%	77%	83%	90%
Sales growth (YoY)	0%	0%	236%	109%	107%	103%	99%

INVESTMENT SERIES A



PAST FINANCING ROUNDS



Round	Year	Capital [CHF]	Rating [CHF]	Investors	Intended use	Milestones	External cap. (FK) Equity (EK)	Shareholdings thereafter
Foundation	2020	100k	100k	Founder	Company foundation	Presence, research partnerships, development partnerships	100% EK	Founders: 100%, Private/HNWI: 0%, Angels: 0%, Institution: 0%, VCs: 0%
Pre-seed	2021	250k	695k	Industrialist or institution	Development of the first prototype, first patent applications, establishment of infrastructure, quality system	Infrastructure for research and development created, patent applied for, proof of concepts launched	100% EK	Founders: 66%, Private/HNWI: 0%, Angels: 0%, Institution: 34%, VCs: 0%
Seed	2022	4'000k	100'000k	Retail, HNWI, business angels, institutional investors	Development team, production, patent, quality system	Production of the first modules, sale of the first modules, market development and preparation of letters of intent, capsule development	100% EK	Founders: 90%, Private/HNWI: 5%, Angels: 0%, Institution: 5%, VCs: 0%
Series A (ongoing)	2024	10'000k	125'000k	HNWI, Business angels, institutional investors, Fund, VC	Development team, production, patent, quality system	n.a.	100% EK	n.a.

FINANCING ROUND SERIES A

Name of the round	Series-A-2
Capital requirements	CHF 10 million
Capital already secured	CHF 1 million
Non-binding commitments	CHF 5 million
Pre-money valuation	CHF 125 million
Post-money valuation	CHF 135 million
Structure of the investment	100 % equity
Minimum ticket size for private investors	CHF 500,000
Maximum allocation per investor	CHF 10 million



USE OF FUNDS

Scaling

- Automation of in-vitro propagation
- Scaling of capsule production
- Increase in container production capacity
- Onboarding of manufacturers and distributors
- Development of further in-vitro protocols
- Establishment of industrial R&D

Market development

- Implementation of the LOIs
- Market entry in the EU
- Preparation and market entry USA and U.A.E.
- Manufacturers, distributors and service providers
- Structuring the sales organization

Innovation

- Expansion of the patent family
- Industrialization of optimization systems and automation of in-vitro cloning and capsule filling.
- Scaling the plant database
- Expansion of digitalization to the entire value chain

INVESTMENT EXAMPLE




Price per share	CHF 125.00
Number of shares	4'000
Investment total	CHF 500,000.00

Income in a realistic scenario [CHF]							
	2024	2025	2026	2027	2028	2029	2030
Share of dividends				7'380.62	61'824.15	165'911.30	331'843.33
Share of imputed enterprise value 2030							3'266'571.94
Total income				7'380.62	61'824.15	165'911.30	3'598'415.27
Total dividends 2030	566'959.40						
Total income 2030	3'833'531.34						
Total ROI realistic scenario	767%						

Income in an optimistic scenario [CHF]							
	2024	2025	2026	2027	2028	2029	2030
Share of dividends			699.01	17'204.11	83'983.75	217'805.05	487'961.69
Share of imputed enterprise value 2030							4'815'011.63
Total income			699.01	17'204.11	CHF 83'983.75	217'805.05	5'302'973.33
Total dividends 2030	807'653.62						
Total income 2030	5'622'665.25						
Total ROI optimistic scenario	1125%						

PRE-MARKET VALUATION



pwc

This valuation was prepared as part of the "Startup Valuation Program" of Pricewaterhouse Coopers Switzerland. The detailed report is available on request.

EXIT STRATEGIES



STRATEGY A: M&A

We are developing a strategy and products for a major manufacturer of nutritional supplements and cosmetics and are working with this company to the point where we can prepare an exit scenario through a takeover.

The exit scenario could become relevant for the first time after FY5.



STRATEGY B: IPO

CAPSERO grows over time and an IPO is used to raise additional funds.

This is a long-term scenario and could become relevant for the first time after FY7.



Head office: CAPSERO AG, Dammstrasse 36, 4142 Münchenstein, Switzerland
Operations: CAPSERO AG, Schaffhauserstrasse 101, 4332 Stein, Switzerland

info@capsero.com | www.CAPSERO.com